Drug Profile
EP 201
Alternative Names: EP-201Latest Information Update: 25 Jul 2022
Price :
$50
*
At a glance
- Originator EpiThany
- Class Antigens; Antineoplastics; Cancer vaccines; Immunotherapies
- Mechanism of Action Immunostimulants; Th1 cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Ovarian cancer
Most Recent Events
- 25 Jul 2022 EP 201 is still in phase II trials for Ovarian cancer in USA (Parenteral) (EpiThany pipeline, July 2022)
- 05 Oct 2016 Phase-I clinical trials in Ovarian cancer in USA (Parenteral) (EpiThany pipeline, October 2016)